Michael Khalil is a clinical neurologist whose research focuses on pathophysiologic mechanisms of neuroimmunological disorders with particular interest in Multiple Sclerosis. His main aim is to develop and validate body fluid biomarkers for disease progression, different disease phases/stages and response to disease modifying treatments. Research findings are being evaluated and interpreted in strong association with imaging (conventional and non-conventional MRI at 3T) findings of the central nervous system and detailed clinical follow-up data. This shall ultimately serve to define patient subgroups and develop more effective treatment regimes and drugs. Currently his group investigates biomarkers related to increased brain iron deposition and the development of brain atrophy in MS.